Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Details : Korlym (mifepristone) is an approved selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated in phase 4 for cushing syndrome.
Brand Name : Korlym
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 29, 2024
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Details : Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Brand Name : Korlym
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2024
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Details : Korlym (mifepristone) blocks cortisol receptors to manage hyperglycemia in adults with Cushing's syndrome who have type 2 diabetes or glucose intolerance.
Brand Name : Korlym
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2024
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Therapeutic Solutions’ Res Nova Bio Reports Positive Data in Advanced Cancer
Details : FloraStilbene (mifepristone and pterostilbene) aims to stimulate the immune system in advanced breast cancer patients, with preclinical data showing efficacy in a triple-negative breast cancer model.
Brand Name : FloraStilbene
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 03, 2024
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene™
Details : FloraStilbene (RU486 and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Brand Name : FloraStilbene
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2023
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cure Stat Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Cure Stat Rx will manufacture first in class breast cancer immunotherapy product FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast can...
Brand Name : FloraStilbene
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cure Stat Rx
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?